Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

417 - Oncolysis dominated therapeutic effect of LCMV-GP – pseudotyped vesicular stomatitis virus in a syngeneic lung cancer model

Date

14 Dec 2018

Session

Poster Display session

Presenters

Guido Wollmann

Citation

Annals of Oncology (2018) 29 (suppl_10): x24-x38. 10.1093/annonc/mdy487

Authors

G. Wollmann1, L. Schreiber1, C. Urbiola1, K. Das1, B. Spiesschaert1, J. Kimpel2, F. Heinemann3, B. Stierstorfer3, P. Müller4, M. Petersson5, P. Erlmann5, D. von Laer2

Author affiliations

  • 1 Christian Doppler Laboratory For Viral Immunotherapy Of Cancer, Medical University of Innsbruck, 6020 - Innsbruck/AT
  • 2 Division Of Virology, Medical University of Innsbruck, 6020 - Innsbruck/AT
  • 3 Target Discovery Research, Boehringer Ingelheim GmbH & Co. KG, Biberach a.d. Riss/DE
  • 4 Cancer Immunology And Immune Modulation, Boehringer Ingelheim GmbH & Co. KG, Biberach a.d. Riss/DE
  • 5 Research And Development, ViraTherapeutics GmbH, 6020 - Innsbruck/AT
More

Resources

Abstract 417

Background

The therapeutic effect of oncolytic virotherapy is mediated largely by two mechanisms; direct oncolysis due to tumor-selective viral replication and the simultaneous activation of innate and adaptive immune responses with the potential of long-lasting tumor remissions. The chimeric vesicular stomatitis virus pseudotyped with LCMV glycoprotein (VSV-GP) has been previously reported to have both a rapid lytic cycle and a broad tumor tropism. In this study, we demonstrate its therapeutic potential in the syngeneic lung cancer model LLC1.

Methods

To address the effect of IFN sensitivity of LLC1 cells to VSV-GP mediated oncolysis, we generated interferon receptor deficient cells (LLC1-IFNAR1-/-) using TALENs. Therapeutic efficacy of VSV-GP was assessed in vivo in syngeneic C57BL/6 mice and athymic nude mice bearing subcutaneous tumors. The mechanisms of VSV-GP treatment effect were investigated using bio-luminescent imaging (BLI), immunohistochemistry, multiplex ELISA and Nanostring® technology.

Results

The ability of VSV-GP to infect and lyse LLC1 cancer cell-lines in vitro was abrogated by exogenously applied interferon (IFN) type I indicating a dependence of the oncolytic effect on defects in the IFN response of cancer cells. Interferon resistance of LLC1-IFNAR1-/- cells correlated with prolonged intratumoral viral replication and improved therapeutic outcome in vivo, as demonstrated by using a matched pair of LLC1 wildtype and LLC1-IFNAR-/- tumors. Additionally, BLI revealed successful tumor-to-tumor spread of viral progeny in bilateral tumor models. VSV-GP therapy was associated with enhanced T cell infiltration and upregulation of various immune-associated genes. Interestingly, the efficacy of VSV-GP therapy in treating LLC1-IFNAR-/- tumors was not diminished by the absence of CD8+ T cells and cured mice were not immune to tumor rechallenge indicating a predominant lytic effect.

Conclusions

The treatment effect of VSV-GP in LLC1-IFNAR-/- lung cancer model is primarily lytic with negligible contribution of adaptive immunity despite strong activation of both innate and adaptive immune signatures.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Medical University of Innsbruck.

Funding

ViraTherapeutics GmbH, Innsbruck, Austria.

Disclosure

G. Wollmann: Scientific advisor: Boehringer Ingelheim GmbH & Co. KG. B. Spiesschaert: Part time employment: ViraTherapeutics GmbH; Part of Christian Doppler Laboratory. F. Heinemann, B. Stierstorfer, P. Müller: Employment: Boehringer Ingelheim GmbH & Co. KG. M. Petersson, P. Erlmann: Employment: ViraTherapeutics GmbH. D. von Laer: Inventor of VSV-GP; Minority shares: ViraTherapeutics GmbH (which holds the intellectual property rights for VSV-GP); Scientific advisor: Boehringer Ingelheim. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.